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Abstract: Current evidence suggests that botulinum neurotoxins (BoNTs) A1 and B1, given 
locally into peripheral tissues such as skin, muscles, and joints, alter nociceptive processing 
otherwise initiated by inflammation or nerve injury in animal models and humans. Recent 
data indicate that such locally delivered BoNTs exert not only local action on sensory 
afferent terminals but undergo transport to central afferent cell bodies (dorsal root ganglia) 
and spinal dorsal horn terminals, where they cleave SNAREs and block transmitter release. 
Increasing evidence supports the possibility of a trans-synaptic movement to alter 
postsynaptic function in neuronal and possibly non-neuronal (glial) cells. The vast majority 
of these studies have been conducted on BoNT/A1 and BoNT/B1, the only two 
pharmaceutically developed variants. However, now over 40 different subtypes of botulinum 
neurotoxins (BoNTs) have been identified. By combining our existing and rapidly growing 
understanding of BoNT/A1 and /B1 in altering nociceptive processing with explorations of 
the specific characteristics of the various toxins from this family, we may be able to discover 
or design novel, effective, and long-lasting pain therapeutics. This review will focus on our 
current understanding of the molecular mechanisms whereby BoNTs alter pain processing, 
and future directions in the development of these agents as pain therapeutics.  
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1. Introduction 
Botulinum Neurotoxins (BoNTs) are the most potent toxins known to humankind and are the 
causative agent of the serious and potentially fatal paralytic disease botulism [1]. About 35–40 years 
ago, it was shown that local intramuscular injection of low doses of BoNTs resulted in local, long-lasting, 
but reversible paralysis of the injected muscle [2,3]. This property of BoNTs proved useful for treatment 
of strabismus [3,4]. These landmark studies together with the development of purification techniques 
and standardized detection assays [5] led to the development of BoNTs as widely used pharmaceuticals 
to produce paralysis of additional therapeutic targets, including the facial musculature for cosmetics and 
large muscle groups to manage debilitating muscle spasms (as in torticollis and back spasms) [6,7]. 
Other applications that have evolved and for which FDA approval has been granted include management 
of hyperactive bladder and hyperhidrosis [6,7]. Common to all of these applications is that the BoNTs 
are taken up into the motor neuron terminal at the neuromuscular junction or parasympathetic axon 
terminal, where the toxin acts to block the release of acetylcholine [8]. Importantly, these effects are 
consistently achieved by a localized action after local delivery without systemic redistribution [2–4]. 
Early on in the use of BoNTs for treatment of spasticity disorders it was incidentally observed that the 
pain associated with muscle spasms was significantly attenuated to a degree that exceeded that which 
would have been anticipated from the simple reduction of muscle contracture [9]. Of particular interest 
was the appreciation several years later that pericranial injection of BoNT/A1 and B1 could relieve 
symptoms in some forms of chronic migraine [10–22]; however, some contradictory findings were also 
reported [23–25]. Intramuscular BoNT/A1 injections across the head and neck was FDA-approved as a 
treatment for chronic migraine headaches in 2010. A robust literature now shows that the local delivery 
of BoNT/A1 or BoNT/B1 has profound effects upon a variety of pain states in preclinical models, and, 
importantly, in clinical pain syndromes. In this review, we will consider i) the mechanisms of action of 
BoNT/A1 and /B1 in altering cellular function, ii) the effects of BoNT/A1 and /B1 on pain behavior 
phenotypes in preclinical models and in human pain states, iii) the likely mechanisms underlying this 
action and iv) future directions for the development of novel BoNT-based therapeutics to target nociceptive 
processing, and the value of investigating the diversity of the large family of BoNTs in this endeavor.  
2. Botulinum Neurotoxin Structure and Function 
BoNTs are a large family of proteins that are produced by a diverse group of gram positive, spore 
forming anaerobic bacteria termed Clostridium botulinum and by a few strains of Clostridium butyricum, 
sporogenes, and baratii [26,27]. At least 40 different subtypes of BoNTs have been described today. 
The current nomenclature differentiates newly identified BoNTs as novel subtypes based purely on an 
amino acid difference greater than 2.5% [28], and many more variants exist that are not classified as 
unique subtypes. The BoNTs are classified into seven serotypes (A though G) based primarily on 
antigenic specificity [29], and the subtypes within each serotype are denoted by a number following the 
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letter. All BoNTs are modular proteins constructed of a 100 kDa heavy chain (HC) and a 50 kDa light 
chain (LC) linked by a disulfide bond (Figure 1). The HC is divided into a C-terminal receptor binding 
domain (HCR) and an N-terminal translocation domain (HCN) [30]. Cell entry by BoNTs proceeds via 
a multi-step process (Figure 2). The HCR of BoNTs binds to specific protein and ganglioside receptors 
on the cell surface, leading to endocytosis of the HC-LC complex. In the acidic environment of the 
endocytic vesicle, protonation causes a conformational shift in the BoNT protein resulting in 
incorporation of the HC into the endocytic vesicle membrane to form a channel through which the LC 
is translocated into the cytosol [30–32]. The disulfide bond is reduced inside the cell’s cytosol, releasing 
the LC to refold to an enzymatically active conformation [8,33]. The BoNT LC is a zinc-dependent 
endoprotease that, once inside the cell, cleaves intracellular SNAREs (soluble N-ethylmaleimide  
-sensitive-factor attachment protein receptors) at highly specific consensus sites. This cleavage prevents 
SNARE-mediated protein transport and transmitter release [1,34], which, at the neuromuscular junction, 
results in a failure of muscle innervation and thus flaccid paralysis. An important characteristic of BoNT 
LC is that it is capable of persisting in an active configuration in the cytosol for days to months, 
depending on the BoNT serotype. During that time, the LC continues to cleave its target SNARE, which 
accounts for the associated duration of action of the respective toxin [8,35]. 
 
Figure 1. Botulinum Neurotoxin A1 (BoNT/A1): The 50 kDa light chain (LC) (blue) is 
linked to the 100 kDa heavy chain (HC) (green, yellow, and red). The HC is functionally 
divided into the translocation domain (HCN) (green) required for transport of the LC from 
the endosome into the cell cytosol, and the receptor binding domain (HCR) (yellow and red) 
through which BoNT binds to the cell surface. Crystal structure image from the Protein 
databank doi:10.2210/pdb3bta/pdb [36]. 
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Figure 2. BoNT uptake mechanism and targets: BoNT consists of heavy chain (HC) and 
light chain (LC). Heavy chain binds to the ganglioside and protein receptors (1) and is 
endocytosed (2,3). The acidic environment in the endosomes leads to conformational changes 
resulting in membrane insertion of the HC and LC translocation into the cell cytosol (4).  
In the cytosol, the disulfide bond linking HC and LC is reduced, releasing the LC into the 
cytosol. The LC of BoNT-B/D/F/G specifically cleaves VAMP on the vesicle, BoNT-A/C/E 
cleaves SNAP-25 and BoNT-C also cleaves syntaxin on plasma membranes (5),  
thus inhibiting the vesicular fusion and blocking the neurotransmitter release (6).  
Not shown is the potential role of cytosolic SNAREs mediating the trafficking of receptor 
and channel subunit protein to the membrane in lipid raft scaffolding. 
3. Peripheral Delivery of Botulinum Toxins and Nociception in Preclinical and Human Models 
Pain has a profound effect upon the well-being of the human and animal, and treatment of pain 
remains a high priority. Here, we will consider the actions of BoNTs delivered peripherally into the skin 
and muscles to locally alter pain states. In this discussion, it is heuristically useful to consider the effects 
of these toxins on the distinct nociceptive processing generated by acute high intensity stimulation, tissue 
injury/inflammation and nerve injury. Mechanistic studies with clinical implication involving the 
intrathecal delivery of these toxins will also be considered in the targeting of these toxins. We note that 
the majority of work to date has focused on the commercially available BoNT/A1 and /B1 serotypes. 
While these enabling observations are exciting, we argue that they make the case for further 
investigations into the actions on pain processing of other serotypes and subtypes. Tables 1 and 2 
summarize the clinical and pre-clinical findings of BoNT in different pain models. 
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Table 1. Summarizes the clinical studies examining the effectiveness of botulinum 
neurotoxins (BoNT)/A1/B1 in several pain conditions. 
No 
Type of pain 
condition/Model 
BoNT 
serotype 
Outcome Interpretations References 
1) 
Migraine 
Acute Migraine  
(<15 
attacks/month) 
BoNT/A1 
Positive 
Reductions in migraine severity and headache 
frequency 
[15–17] 
Negative 
No significant differences observed between the 
placebo and BoNT treatment group. Few studies 
observed a trend however not significant 
[23,24] 
Chronic Migraine  
(>15 attacks 
/month) 
BoNT/A1 
Positive 
Pooled result of PREEMPT trials favored both 
primary and secondary endpoints. Reduction in 
cephalic allodynia associated with chronic 
migraine 
[13,14,18,21,22]
Negative 
Mild or no effect was observed in this 
randomized controlled study 
[25] 
BoNT/B1 Positive 
Chronic migraineurs significantly responded to 
Rimabotulinumtoxin (BoNT/B1) 
[19,20] 
2) Chronic joint pain BoNT/A1 
Positive 
BoNT/A1 showed significant effect in treating 
refractive shoulder joint pain 
[37,38] 
Positive Efficacy in painful knee and joint arthritis [39,40] 
3) 
Neuropathic pain 
Mononeuropathy BoNT/A1 Positive 
BoNT treatment was effective in treating 
trigeminal neuralgia and peripheral nerve injury 
[41–48]  
Polyneuropathy BoNT/A1 Positive 
Effective in cases of post-herpetic neuralgia 
Efficacy reported for diabetic neuropathy 
[49–52] 
4) 
Chronic low back 
pain 
BoNT/A1 Positive 
Treatment in paraspinal muscles reduced pain in 
refractory low back pain patients 
[53,54] 
5) Myofascial pain BoNT/A1 Positive BoNT reduced focal myofascial pain syndrome [55,56] 
6) 
Evoked nociception model 
Capsaicin BoNT/A1 
Positive 
BoNT inhibited capsaicin induced flare alone or 
both flare and evoked nociception 
[57–60] 
Negative Showed no effect on any end points [61–63] 
Glutamate BoNT/A1 Positive 
Reduced glutamate evoked pain and local 
increase in skin blood flow 
[64] 
Thermal Injury BoNT/A1 Negative 
Evoked primary or secondary hyperalgesia was 
not altered by BoNT 
[65] 
7) Acute thresholds BoNT/A1 Negative 
No effect upon normal thermal and mechanical 
pain thresholds in quantitative testing paradigm 
[57,61–63] 
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Table 2. Pre-clinical (in vivo and in vitro) studies examining effectiveness of BoNT/A1 and 
B1 in several pain models. 
No 
Type of pain 
condition/Model 
BoNT 
serotype 
Species Outcome Interpretations References 
1) 
Inflammatory pain models 
Formalin BoNT/A1/B1 Rat/mouse Positive 
Peripheral BoNT shows little or no effect on phase I with 
long term inhibition in phase II formalin flinching and 
neuronal c-fos activation. Inhibition of neurotransmitter 
release. Cleavage of SNARES in DRG/TG and spinal cord
[66–73] 
Capsaicin BoNT/A1/B1 Rat/mouse Positive 
Peripheral BoNT reduces capsaicin evoked flare, 
nociceptive behavior and inhibition of neurotransmitter 
release. Cleavage of SNARES in TG and nucleus caudalis
[67,74,75] 
Carrageenan 
BoNT/A1 Rat Negative Lack of effect on peripheral inflammation and pain [76,77]  
BoNT/A1/A2 Rat Negative 
No effect of BoNT was observed in carrageenan evoked 
flare and plasma extravasation 
[77–79]  
Arthritis 
BoNT/A1 Rat Positive 
BoNT reduced allodynia in CFA induced knee arthritic 
animals 
[80]  
BoNT/A1 Dogs Positive Intraarticular BoNT reduced indices of pain [81–83] 
2) 
Neuropathic pain 
Mononeuropathy 
(peripheral and 
infraorbital nerve 
ligation, ventral root 
transection) 
BoNT/A1/B1 Rat/mouse Positive 
BoNT reduced allodynia following peripheral treatment. 
Suggests central action of BoNT 
[74,84–87] 
Polyneuropathy 
(Chemotherapeutics, 
diabetes) 
BoNT/A1 Rat/mouse Positive 
Reduced thermal and mechanical hyperalgesia with 
bilateral effects 
[78,84,88,89]
3) 
Trigeminal pain 
models 
BoNT/A1/B1 Rat/mouse Positive 
Orofacial BoNT reduced capsaicin evoked nocifensive 
behavior, inhibited trafficking of TRPV1 to plasma 
membrane, cleavage of SNARES 
[75,90] 
Decreased mechanical sensitivity of temporal muscle 
nociceptors. Inhibited responses to mechanical stimulation 
of dura to supra threshold forces 
[91] 
 In vitro (cell/organ culture studies) 
1) 
Dorsal root ganglion 
sensory neuron cell 
culture 
BoNT/A1 Rat Positive 
BoNT cleaves neuronal SNARES and prevents release of 
neurotransmitters 
[92,93] 
2) 
Trigeminal sensory 
neuron organ/cell 
culture 
BoNT/A1 Rat Positive 
BoNT inhibits CGRP secretion from TG neuronal culture [94] 
Modify expression of inflammatory markers both in 
neurons and glial cells 
[95] 
3) 
Trigeminal satellite 
glial cell culture 
BoNT/A1 Rat Positive 
BoNT cleaves glial SNARES and inhibited glutamate 
release 
[96] 
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3.1. Acute Nociception  
3.1.1. Mechanisms 
Acute high intensity stimuli lead to a pain state referred to the site of stimulation. This pain state 
reflects the intensity-dependent activation of populations of small primary afferents (A∂ and C fibers) 
by high intensity thermal or mechanical stimuli, which release excitatory transmitters (amino acids and 
peptides) from their terminals in the spinal dorsal horn. These transmitters activate second order spinal 
dorsal horn neurons that project supraspinally [97]. Absent the stimulus, the afferent traffic resolves and 
the pain sensation abates. 
3.1.2. Botulinum Toxins 
Intraplantar delivery of both BoNTs, A1 and B1, at doses that do not obstruct motor function, have 
no effect upon the behavioral escape response otherwise evoked by acute high intensity thermal or 
mechanical stimuli (pin prick), or chemical stimulation such as evoked paw withdrawal or local chemical 
irritants (e.g., phase 1 of the biphasic flinching response otherwise evoked by intraplantar or orofacial 
formalin) [66–73]. It is important to emphasize that nociceptive threshold testing must occur in the 
absence of disabling motor function. Such end points would include absence of changes driven by  
non-noxious stimulation, including corneal touch-evoked blink, hind paw placing and stepping reflexes, 
weight bearing or symmetrical ambulation. Adhering to such robust end points would indicate that any 
observed changes in escape latency or pain thresholds were not the result of a failure in the  
motor-dependent ability to produce the analgesic end point (e.g., paw withdrawal/flinching) [66,67,71,98]. 
It should be noted that in general the doses employed in these studies are typically in the range of  
0.5–1 U, where 1 U is the dose that leads to mortality in half of the mice upon intraperitoneal injection. 
This reflects upon the fact that the intraplantar or subcutaneous injections result in a restricted 
redistribution as compared to that achieved with intraperitoneal delivery [67,84,99]. 
In human studies, subcutaneous BoNT/A1, as in the preclinical studies, had no effect upon normal 
thermal or mechanical pain thresholds in quantitative sensory testing paradigms [57,61–63]. As will be 
reviewed further below, given the effects of BoNT/A1 and BoNT/B1 on afferent transmitter release, 
these observations, showing no change in acute thresholds, are unexpected.  
3.2. Tissue Injury/Inflammation  
3.2.1. Mechanisms 
In the face of tissue injury and inflammation, the associated pain state is characterized by:  
i) an ongoing sensation that persists in the absence of the injuring stimulus; and, ii) the presence of a 
hyperalgesia where an innocuous or mildly noxious stimulus is perceived to be aversive or noxious  
(e.g., hyperalgesia). Typically, once the underlying pathology is resolved (e.g., wound healing, 
resolution of inflammation), the pain and hyperalgesia may also resolve. The ongoing pain state and 
enhanced responsiveness reflects two elements. First, nociceptive afferents innervating the 
damaged/inflamed tissue are acted upon by active factors released by vascular cells (neutrophils, 
lymphocytes, platelets) and resident cells of the innate immune response (macrophages and mast cells) [100]. 
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These factors act upon eponymous receptors expressed by many small afferents to depolarize the 
terminals leading to continuous afferent input and an enhanced response of the terminal to subsequent 
afferent stimulation [101]. This terminal sensitization is secondary to the activation of terminal kinases 
which phosphorylate terminal receptors (such as for the bradykinin receptor) [102] and ion channels  
(e.g., TRPV1, voltage gated sodium and calcium channels) [103–107]. Secondly, spinal systems in the 
face of ongoing high frequency small afferent activation can display an enhanced input-output function, 
referred to as wind up and/or central sensitization [101,108]. The pharmacology of this central 
facilitation is equally complex and reflects: i) a progressive depolarization of the second order neuron; 
ii) activation (phosphorylation) of spinal kinases that enhance the reactivity of the second order 
membrane by phosphorylating membrane channels and receptors [109–111]; iii) changes in the transport 
of various excitatory receptor and channel subunits to the membrane [112–114], and iv) activation of 
dorsal horn non-neuronal (astrocyte and microglia) cells leading to release of a variety of pro excitatory 
products [115,116]. These cascades are ubiquitous and relevant to all inflammatory states, including 
those arising from the skin, muscle, bone, and visceral tissues such as the gut and the meninges. These 
pain states have several important characteristics. First, pain states arising from viscera (e.g., irritable 
bowel) and bone (e.g., cancer), for example, display a referred pain component, in which the 
visceral/bone afferent input is referred to the superficial (cutaneous) dermatome which projects by a 
somatic afferent to the same spinal second order neurons. This referral model is particularly relevant to 
phenomena such as migraine, wherein meningeal afferents activated by local meningeal inflammatory 
processes activate neurons in the nucleus caudalis that also receive input from cutaneous cranial  
afferents [117]. Second, it has become appreciated that, in the face of persistent inflammation, the 
inflammatory pain phenotype may progress to one that involves nerve injury. In the case of joint 
inflammation, pain may continue after resolution of the inflammation. The mechanism of this transition 
to a chronic pain state is not well understood, but several changes are relevant. Persistent peripheral 
inflammation may lead to: i) increased expression of ATF-3 in the dorsal root ganglion (indicative of an 
injury response); ii) spinal cord glial activation [118,119]; and, iii) peripheral terminals may begin to 
express nerve injury epitopes suggestive of sprouting [120]. Thus, mechanisms of pain associated with 
tissue and nerve injury may occur in conditions such as osteoarthritis where inflammatory markers (joint 
volume, neutrophils) may be minimally present [121–123].  
3.2.2. Botulinum Toxin  
Unilateral intraplantar delivery of BoNT/A1 and /B1 at doses of 0.5 U or less exhibit a local, typically 
homolateral anti-hyperalgesia as measured by thermal and mechanical thresholds in rodent models of 
inflammation (e.g., intraplantar carrageenan, or formalin) [66,67,76,78]. These effects, where reported, 
have an onset of 2 to 24 hours and a duration of action in excess of 14 to 21 days [67]. In horses,  
intra-articular BoNT/A1 can attenuate lameness in a model of acute synovitis [124]. Similarly, in dogs 
with chronic osteoarthritis, intra-articular BoNT/A1 was found to reduce indices of pain [81–83]. The 
typical ipsilateral effect emphasizes that the BoNTs did not exert a bilateral effect and thus were not 
likely due to a simple systemic redistribution at the employed doses. We note that, while ipsilaterally 
delimited effects have been observed, particularly at lower doses, bilateral anti-hyperalgesia [78,88,89] 
and bilateral muscle relaxation [125] after unilateral delivery into the paw have been reported. The 
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likelihood of multi-segmental effects on motor and sensory function in humans has been expertly 
reviewed and discussed in detail elsewhere [126].  
In humans, myofascial pain syndromes, characterized by activation of multiple bilateral local pain 
state trigger points, have been shown to be attenuated by local delivery of BoNT/A1 [127,128]. 
However, systematic trials appear to be lacking [129,130]. Intra-articular delivery of BoNT/A1 has been 
shown to have attenuating effects upon inflammatory and chronic joint pain in the shoulder [37–40,131]. 
Paraspinal muscular application of BoNT/A1 reduced refractory low back pain in the majority of patients [53]. 
To further characterize the effects of peripheral BoNTs on human pain behavior, validated 
experimental models have been examined. Subcutaneous capsaicin, resulting in persistent small afferent 
activation, evokes a local pain sensation referred to the site of injection, a primary and secondary 
hyperalgesia and an increase in local cutaneous blood flow (flare). Pretreatment with subcutaneous 
BoNT/A1 was reported to diminish pain (hyperalgesia) and blood flow (flare) [57]. Others reported 
either an effect only upon capsaicin induced flare [132] or no effect on any end point [61–63]. Studies 
examining the effects of pretreatment with subcutaneous BoNT/A1 for the pain and local increase in 
skin blood flow evoked by subcutaneous glutamate observed a significant inhibition with peak effects 
by seven days and a return to baseline by 60 days [64]. Following focal thermal injury, the associated 
primary and secondary hyperalgesia was not altered by BoNT/A1 in a double-blinded crossover  
study [65]. Taken together, these data reveal mixed indications of efficacy of BoNTA1 in reducing 
inflammatory pain states, and further studies are needed. 
3.3. Peripheral Nerve Injury 
3.3.1. Mechanisms  
Injury to the peripheral nerve trunk or terminals (e.g., yielding mono and poly neuropathies, 
respectively) leads to a paradoxical pain state in which the individual reports an ongoing pain condition 
(dysesthesia) and an exaggerated response to light touch ipsilateral to the nerve injury or bilateral. The 
tactile hypersensitivity is mediated by the activation of large (low threshold) Aβ axons. In animal 
models, mononeuropathies arise from ligation of nerve roots (Chung model neuropathy), partial nerve 
ligations (Shir model) or nerve compressions (Bennett model) [133,134], and poly-neuropathies may 
arise from toxic effects from chemotherapy (vinca alkaloid, platin drugs) [135] or from diabetes [136]. 
Mechanistically, these changes in neuraxial function result from the development of ectopic activity in 
the sprouting terminals of the injured axons and in their DRG [137]. While not necessary for afferent 
conduction, DRG activation can be a robust source of afferent traffic into the dorsal horn [138]. This 
increased activity results from a number of neuro-inflammatory responses which contribute to 
development and maintenance of the neurogenic pain state: i) increased DRG transcription factor  
activity [139] associated with altered channel (e.g., increased sodium/decreased potassium) receptor 
(e.g., increased purine, glutamate) protein expression [140–142]; ii) migration of inflammatory cells into 
the DRG that release lipid mediators, cytokines and growth factors which can activate the neighboring 
sensory neurons [143–145]; iii) sprouting of sympathetic terminals into the neuroma and DRG, which 
can activate afferent input [146]; iv) activation of DRG satellite cells (glia) [144,147], and development 
of an enhanced excitatory coupling between these satellite cells and dorsal root ganglion neurons [148], 
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reflecting increased trafficking of GAP junction and excitatory purine receptor expression [149]. 
Following nerve injury, the increased ongoing afferent input can lead to a central facilitatory response, 
as observed after tissue injury [150]. In addition, nerve injury may lead to changes in spinal processes 
resulting in a loss of inhibitory control over large afferent-evoked excitation that likely lead to the 
phenomena of enhanced sensitivity to light touch (tactile allodynia) [151,152]. Unlike the states 
associated with tissue injury, pain secondary to injury of the peripheral nerve rarely resolves, resulting 
in chronic pain states.  
3.3.2. Botulinum Toxin 
In rodent models, intraplantar delivery of BoNT/A1 and BoNT/B1 in doses of 0.5–1 U has been 
reported to reduce the allodynia observed in mononeuropathy models, including those of peripehral 
nerve ligation [84,85], ventral root transection [86,87], and infraorbital nerve constriction [74], and in 
polyneuropathy models, including those produced by chemotherpeutics [78,84] and diabetes [88]. As 
with the models of inflammation, these effects begin after ~1–2 days and last in excess of 21 days. In 
human case reports and clinical studies, the hyperesthesia observed in post-herpetic neuralgia [49–51], 
diabetic neuropathy [52], and peripheral nerve injury [41–43] is relieved by peripheral BoNT/A1 
treatment. The use of local intramuscular, subcutaneous delivery of BoNT/A1 has also been reported to 
have efficacy in trigeminal neuralgia [44–48], which is a facial mononeuropathy. These data suggest 
that BoNT/A1 and /B1 can reduce neuropathic pain states resulting from peripheral nerve injury.  
4. Effects of Peripherally Delivered Botulinum Toxins on Nociceptive Linkages 
As reviewed in Section 3 above, peripherally delivered BoNT/A1 and /B1 have been studied in mouse 
and rat behavioral models and in human pain states for their effects upon several mechanistically defined 
nociceptive states. Initial work quite reasonably hypothesized that the efficacy of peripherally delivered 
BoNT/A1 in treating some pain conditions, such as hypertonic states (e.g., torticollus and back spasm), 
was secondary to muscle relaxation. This hypothesis, however, did not generate continued support, as 
pain alleviation in conditions like cervical dystonia was noticed much earlier than the muscle  
relaxation [9], and analgesic efficacy was observed in pain states where muscle tension was not 
considered to be a primary issue, such as in migraine [9,153] or neuropathic pain states [154]. Current 
evidence suggests several possible local and spinal mechanisms of action, which might account for the 
behaviorally defined antinociceptive actions of the peripherally delivered BoNT/A1 and /B1. The effect 
of BoNT/A1 and /B1 on these pain states reflects upon the systems with which they interact and the 
cellular effects in these systems. The primary effect of the BoNT toxins is to cleave SNAREs. SNAREs 
are densely localized in the lipid rafts that organize transport of specific proteins such as receptor/channel 
subunits and enzymes to the cell membrane of a variety of cell types including neurons and  
glia [155–160]. Thus, while the role of SNARES in mobilizing synaptic vesicles is well known, there 
are other intracellular transport processes that employ these SNARE targets, and their cleavage would 
thus impact upon other cellular processes [90,161–164]. Many of these specific processes are known to 
mediate nociceptive processing at the level of the primary afferent and the spinal dorsal horn [90,165] 
and studies supporting these mechanisms are summarized in Table 3. These components and their 
contributions to the analgesic effects of peripherally delivered BoNTs will be considered below.  
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4.1. Local Action on Peripheral Afferent Terminal 
There is strong and diverse evidence that, as shown in Figure 3, locally delivered BoNTs can be taken 
up in the terminal of the sensory afferent, and local effects exerted by this toxin will be considered below.  
 
Figure 3. Schematics of possible mechanisms of action of peripherally applied BoNT/A1 
and /B1 upon nociceptive processing: (A) Periphery: (1) At the site of injection BoNTs are 
endocytosed into the local peripheral afferents, where they cleave SNAREs, thereby 
inhibiting vesicular fusion and exocytosis of neurotransmitters. This in turn would block 
vasodilation, plasma extravasation, and activation local inflammatory cells. (2) BoNTs may 
also regulate SNARE-mediated cell surface expression of a variety of receptors and channels 
implicated in peripheral sensitization (e.g., TRPV1). (3) Another hypothesis is that BoNTs 
may enter local resident cells (e.g., mast cells) or migrating cells (e.g. neutrophils) otherwise 
evoked by injury or inflammation and may directly block the release of cytokines or  
pro-inflammatory molecules. These release products can activate and sensitize local small 
afferent terminals. (B) Spinopetal transport: (4) Following endocytosis in the peripheral 
terminals, some of the BoNT appears to undergo retrograde transport along the axon.  
(5) These transported BoNTs reach the dorsal root ganglion (DRG) neuron and cleave 
SNAREs in the DRG neurons to block vesicular release of neurotransmitters into the 
extracellular milieu of the DRG, which would otherwise activate and (6) excite the neighboring 
sensory neurons or (7) closely associated satellite cells. (8) BoNT may further undergo  
intra-vesicular axonal trafficking to the central terminals, where again by truncating 
respective SNAREs, it would inhibit neurotransmitter release, thereby preventing the 
activation of second order neurons and neighboring glial cells. (C) Trans-synaptic actions: 
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BoNTs can undergo long axonal transport in intact form in non-acidic endosomes and may 
possibly undergo transcytosis centrally either to the (9) second order neurons or (10) glial 
cells. Activated glial cells release a plethora of pro-algesic substances (cytokines, chemokines, 
lipids, amino acids) serving to initiate and maintain central sensitization. (11) BoNTs may 
also get transcytosed to excitatory (glutamatergic) or inhibitory (GABA/glycinergic) 
interneurons and may act to block their neurotransmitter release resulting in a loss of 
excitatory drive or inhibitory control, respectively). Cleaved SNAREs in the second order 
neurons may interfere with fusion of endosomes that carry the receptors to the membrane. 
(12) Though speculative, if there is transcytosis to second order projection neurons, it is a 
reasonable hypothesis that these BoNT are transported to distal terminals which lie in the 
brainstem and further block the neurotransmission into the brainstem and higher centers. 
4.1.1. Afferent Terminal Uptake/Transport 
BoNTs can be taken up in the peripheral terminal of motor axons to cleave terminal SNAREs and 
block release of acetylcholine. It is now evident that BoNT/A1 and /B1 can also be locally taken up at 
peripheral terminals of sensory axons. In addition to in vitro work showing that BoNTs (primarily 
BoNT/A1/B1) can enter and cleave SNAREs in all neurons and not just motor neurons (reviewed  
in [166]), principal support for this hypothesis of a terminal action in sensory neurons is derived from 
the following observations:  
i) Activation of the peripheral terminals of TRPV1 (+) C-fibers with capsaicin leads to the local 
vesicular release of neuropeptides such as SP and CGRP. This release results in vasodilation and plasma 
extravasation (e.g. neurogenic inflammation) [167]. In rodents, unilateral subcutaneous BoNT/A1 and 
/B1 injections into the paw at intervals as short as 15 min to 1 h will block the ipsilateral, but not 
contralateral, flare and plasma extravasation otherwise evoked by bilateral intraplantar injections of 
capsaicin. This indicates a local block of the release of these small afferent peptides after local BoNT/B1 
treatment [67,75] (Figure 3, #1).  
ii) A block of dural extravasation (from trigeminal afferents innervating the meninges) has been 
similarly demonstrated [74].  
iii) Consistent with these findings, human studies also showed similar effects of BoNT/A1 in 
preventing local cutaneous flare and/or extravasation [57,58,91], though negative results have been  
reported [61–63]. The positive results are consistent with the ability of toxins to prevent afferent 
transmitter release at the peripheral terminal. 
4.1.2. Effects of Local BoNTs on Peripheral Non Afferent Cell Systems  
Locally delivered BoNTs may also affect mechanisms in inflammation other than the afferent 
terminal (Figure 3, #3). Neutrophils, macrophages and mast cells, when activated, will release local 
inflammatory products that activate small afferent terminals [168,169], and all employ SNAREs in their 
transport and exocytosis [170,171]. Macrophages employ a constitutive secretory pathway for the 
secretion of cytokines (e.g., TNF; IL-6 and IL-10), which mediates trafficking to the cell surface by 
SNARE-dependent membrane fusion [172]. Neutrophils store pro-inflammatory cytokines preformed in 
granular packaging and release a variety of highly cytotoxic and stimulatory products including 
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myeloperoxidase and a variety of matrix metalloproteinases through a variety of SNARE- mediated 
processes [171,173,174]. Mast cells play a major role in the local inflammatory response and their 
degranulation leads to the local release of a variety of products, including histamine, high molecular 
weight heparins and cytokines through differential release of granule proteins and distinct secretory 
pathways, and other dilatory products that are similarly mediated by a variety of SNAREs [175]  
(Figure 3, #2). These SNARE dependent secretory processes [176,177] are potentially sensitive to effects 
by BoNTs, provided that the BoNT can enter the relevant cells and cleave a SNARE involved in such 
secretory processes. Entry of BoNTs into mast cells has not been demonstrated so far and the main SNAP 
isoform expressed in human mast cells is the BoNT/A1 insensitive SNAP-23. In addition, it appears that 
VAMP8, rather than the neuronal and BoNT sensitive VAMP1/2, is involved in the secretory process of 
mast cells [177]. However, local BoNT/A1 has been reported to reduce mast cell degranulation in 
rodents [178] and reduce burn-induced itching in humans [179]. Although involvement of SNARE 
proteins in the release of mediators from neutrophils and macrophages has been demonstrated, the direct 
effect of BoNT/A1 on this release thus far has not been adequately explored. Further research efforts are 
warranted to determine whether and how BoNTs may have an effect on neutrophils, macrophages and 
mast cells, and the role that they play in altering the local injury milieu.  
4.1.3. BoNT Effects Upon Sensitized Afferent Terminals  
In studies with dural C fiber afferents, chemical sensitization results in an enhanced afferent  
response [180]. This facilitated response is prevented by local BoNT/A1 [181]. Further, BoNT/A1 
prevented the development of mechanical hypersensitivity of these afferents. Whether this effect reflects 
a direct effect upon mechanisms underlying the initiation of an excitable state in the afferent terminal 
(e.g., mobilization of protein kinases leading to phosphorylation of terminal channels/receptors) [168,169], 
or a potential block of release of active factors from local inflammatory cells (e.g., mast cells, 
macrophages and lymphocytes) remains to be determined (Figure 3, #3). In short, these findings 
emphasize that, overall, while BoNT/A1 may not directly alter the acute activation of afferent terminals 
(e.g., absent effect upon normal sensory thresholds), the toxin can be taken up in an active form in the 
homologous (ipsilateral) sensory afferent terminal and potentially in local pro-inflammatory cells to 
reduce the release of local pro-excitatory products otherwise mobilized by injury and inflammation.  
4.1.4. Trafficking of Receptor Subunits in the Primary Afferent and DRG/TG 
SNAREs are localized in the lipid rafts [182] which play a role in the organization of membrane 
protein insertion [183]. Cleavage of SNARES in DRG/TG neuronal cell culture has been  
reported [92–95,184] and therefore, it would not be surprising if BoNTs had robust effects upon the 
trafficking of a variety of membrane proteins. One example would be the TRPV1 channels [185]. It has 
been shown that during hyperpathic states, TRPV1 receptor function is enhanced by increased trafficking 
of that protein to the plasma membrane at the peripheral and, likely, central terminals and the DRG. 
Evidence suggests that BoNT/A1 hinders recruitment of TRPV1 by affecting regulated exocytosis 
evoked by capsaicin in the trigeminal system [90]. This paradigm suggests a mechanism by which 
BoNT/A1 would be effective in attenuating hyperalgesia in capsaicin-induced trigeminal sensitization 
in humans [58] (Figure 3, #2). Other membrane proteins, the trafficking of which is relevant to facilitated 
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pain states, warrant further study, including those for the glutamate ionophores [186] and the  
TRP channel [187,188].  
4.1.5. Role of Local (peripheral) BoNT Action in Spinal Nociceptive Transmission 
While it is clear that BoNT/A1 and /B1 can exert an effect upon local terminal function, as reviewed 
above, the majority of work to date has not supported a direct effect of these BoNTs on peripheral 
terminal excitability in the normal state, as measured by baseline thermal and mechanical thresholds. As 
noted above, however, it was reported that BoNT/A1 inhibited responses to mechanical stimulation of 
the dura but only to supra-threshold forces [181]. These electrophysiological studies suggested that 
BoNT/A1 is selective for C- but not Aδ-trigeminal meningeal nociceptors. That report is consistent with 
the observation that BoNTs can block release secondary to C-fiber activation, e.g., intraplantar BoNT/A1 
or /B1 block capsaicin-induced flare/plasma extravasation in animal [67,74] and human  
models [58–60,132], reflecting the local stimulatory effects mediated by the TRPV1 receptor on the 
peripheral terminals of the somatic peptidergic C-fiber. While these BoNTs have relatively little effect 
upon normal pain thresholds, they are noteworthy for their action on facilitated states as they occur after 
local inflammation and nerve injury. As reviewed above, local BoNT/A1 and /B1 can block the 
facilitated pain response generated by a variety of stimuli such as intraplantar irritants (e.g., capsaicin, 
formalin, histamine), but it is not apparent whether this peripheral action accounts for the “analgesic” 
actions of local BoNT/A1. Several points should be noted. While BoNT/B1 can have an acute onset at 
the terminal as measured by plasma extravasation after local injection, the effect, for example, on 
formalin-evoked flinching parallels the reduction in DRG SNAREs, which appears to require a longer 
interval (e.g., 24 h) [67]. Further, in the case of the formalin flinching model, local BoNT/A1 or /B1 
have little or no effect upon the first phase flinching but produce a long-term reduction in the second 
phase, which is believed to reflect upon a centrally-mediated facilitation of spinal function generated by 
the conditioning discharge observed during the first phase [67–73,189]. These results suggest that local 
BoNT/A1 and /B1 may alter, with short latencies, the processes leading to changes in transduction and 
the discriminable process of terminal release, thereby preventing pain transmission to the second order 
neuron. There may be additional mechanisms that are at play and are reflected in part by the delayed 
onset of effects that are not local but mediated by transport from the site of delivery.  
4.2. Spinopetal Afferent Transport  
Most pharmaceutical applications of BoNT/A1 and /B1 are based on the premise that BoNTs remain 
and act locally at the injection site. However, recent years have brought to light evidence indicating that 
BoNT/A1 and /B1 may in fact be retrogradely and anterogradely transported after local uptake into 
terminals. While still controversial, such potential transport of BoNTs is important to consider when 
determining their mechanism of action in blocking nociceptive transmission (Figure 3, #4). The different 
lines of evidence supporting spinopetal afferent transport are discussed below.  
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4.2.1. Evidence of Transport of Active BoNT in the Primary Afferent 
Several lines of evidence now indicate that, apart from a local action, BoNT serotypes A1 and B1 are 
taken up and transported in the neuron to distal terminals. Fast axonal transport for BoNT/A1 has been 
demonstrated in the brain [190–192]. However, in contrast, a slow movement of BoNT/A1 was reported 
as cleaved SNAP-25 appeared along neurites and accumulated in the soma over several weeks [193]. In 
the primary afferent, such transport after subcutaneous/intramuscular BoNT/A1/B1 delivery has been 
suggested by data derived from several experimental strategies. 
i) Movement of radiolabeled (iodinated) BoNT/A1 and /B1 has been reported in spinal  
pathways [194–196];  
ii) Cleavage of SNARE proteins (SNAP-25-BoNT/A1 / VAMP-BoNT/B1) has been detected in  
the ipsilateral afferent cell body (DRG/or trigeminal ganglia (TG)) after intraplantar  
delivery [67,71,197,198]. BoNT/A-cleaved SNAP-25 appeared bilaterally in the ventral and dorsal horns 
four days after injection of BoNT/A1 / BoNT/A2, suggesting that catalytically active BoNT/A1 and 
BoNT/A2 were transported via peripheral motor and sensory nerves and transcytosis [199].  
iii) A block of dorsal horn substance P release from primary afferents in the nucleus caudalis evoked 
by supraorbital capsaicin [75] or in the spinal dorsal horn evoked by intraplantar formalin has been 
observed after BoNT/B1 treatment [67]. Further, the same authors showed that peripherally delivered 
BoNT/B1 blocked the evoked release of substance P in the ipsilateral but not contralateral dorsal horn 
(otherwise evoked bilaterally by spinally delivered capsaicin). This demonstrated that the BoNT/B1 
delivered peripherally to one paw had to reach the ipsilateral central afferent terminals where the 
intrathecal capsaicin was acting. 
iv) BoNT/B1 treatment resulted in a block of evoked dorsal horn activity as measured by a decreased 
incidence of evoked dorsal horn c-Fos (+) neurons [67,75]. These observations indicate that peripherally 
delivered BoNT/B1 is taken up at the peripheral afferent terminals and transported in an active form to 
central afferent terminals in both spinal and trigeminal systems, where they cleave SNAREs and prevent 
transmitter release (Figure 3, #5, #8). 
v) Retrograde and anterograde transport of BoNT/A1 in non-acidic organelles has been shown by 
several groups, and estimates indicate speed profiles matching fast microtubule-dependent transport that 
overlaps with TeNT (tetanus neurotoxin) positive carriers in motor neurons and in vivo  
models [74,89,190–192,197,199–202]. However, it is currently unclear what fraction of the locally 
administered BoNT/A1 undergoes such intraneuronal transport, and whether the transport is 
concentration-dependent or differs mechanistically for different routes of administration. 
The likelihood that BoNT/A1 and /B1 transported centrally in the afferent can block transmitter 
release is an important component of understanding their antinociceptive action. However, a common 
thread in the actions of the BoNTs on pain behavior is the general lack of effect upon acute nociceptive 
thresholds. Given the role of small afferents in pain transmission, it is puzzling that blocking central 
terminal release fails to alter acute transmission (if not producing an all-out anesthesia). This conundrum 
is not limited to the action of BoNTs. Studies with intrathecally delivered calcium channel blockers (e.g., 
for the N-type channel) showing effects on afferent transmitter release typically fail to block large 
afferent input (light touch) and have little effect upon acute pain thresholds, yet BoNT/A1 and/B1 
delivery prominently reduces facilitated states in animal models and in humans [203–209]. The reason 
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for this apparent discrepancy remains to be characterized. In short, however, the evidence for the  
time-dependent central transport of BoNT/A1 in an active form in the primary afferent and cleavage of 
SNAREs in the cell body (DRG/trigeminal ganglion) emphasizes the potential for a centrally mediated 
change in transmitter release from the central afferent terminal and, perhaps less appreciated, from its 
cell body (DRG/trigeminal ganglion) [126].  
4.2.2. Role of Cell Body (DRG) Release and BoNT Action 
As noted above, transmitter release of glutamate, among other transmitters, occurs in isolated 
DRG/trigeminal ganglion cells and from associated glia (satellite cells) in cultured cells [96,210,211]. 
Such release likely also occurs in vivo [212]. Electrophysiological recording studies have indicated  
cross-excitation between large (low threshold tactile sensitive) afferents and small (high threshold, 
nociceptive) afferents. This interaction, potentially leading to tactile evoked activation of nociceptive 
input, is enhanced after peripheral injury [213–215]. Current work strongly suggests that such release 
could indeed activate other DRG cells through, for example, glutamatergic receptors [216], some of 
which are on DRG glia (satellite cells) [217] (Figure 3, #6, #7). Given the contribution of such DRG 
release to hyperpathic states initiated by nerve and tissue injury, along with the ability of peripherally 
injected BoNT/A1 and /B1 to cleave DRG and trigeminal SNAREs, it is an intriguing hypothesis that 
such an action by BoNTs could be responsible for their modulation of primary hyperpathia and large 
afferent mediated allodynia. Recent work has indeed shown that BoNT/A1 decreases vesicular release 
of glutamate from satellite cells [96]. A recent study importantly suggests that BoNT/A1 may interfere 
with intra-ganglionic transmitter release and cross-excitation of neighboring neurons to the development 
and maintenance of chronic pain states [218]. This transported action might thus provide an important 
mechanism for altering the hypothesized crosstalk between populations of sensory ganglion cells  
(Figure 3, #6, #7). Further studies in this area will be of considerable interest.  
4.2.3. Effect of BoNT on Central Trafficking 
As reviewed above, SNAREs play a ubiquitous role in the trafficking of several ionotropic and 
metabotropic receptors that contribute to regulating neuronal excitability and synaptic transmission in 
the dorsal horn. The protein receptors are transported to the cell surface in the vesicle membrane that 
fuses via a SNARE mediated process. SNAREs thus play a major role in the induction and maintenance 
of spinal sensitization. SNARE proteins are involved in the mobilization of receptor subunits of  
AMPA [219] and NMDA [220], which are actively involved in the process of dorsal horn  
sensitization [221–223]. Interventions by BoNT in glutamate ionophore trafficking would influence 
facilitated processing, thereby having profound effects upon the generation of facilitated states. In 
cerebellar slices, BoNTs reduce trafficking and block long-term potentiation [161]. The potential that 
BoNTs may affect the processing of pain information by altering receptor trafficking in addition to direct 
effects resulting from a block in exocytosis is an interesting future area of study. 
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4.2.4. Effect of Intrathecally-Delivered BoNTs  
Consistent with these spinal actions outlined above, not surprisingly, intrathecal delivery of BoNT/B1 
has been shown to result in cleavage of spinal SNAREs, blockade of evoked release of afferent 
transmitters and prevention of evoked activation of spinal neurons as indicated by the incidence of  
c-Fos (+) neurons [67,224]. Intrathecal delivery of BoNT/A1 and /B1 has been shown to block the 
second phase of IPLT formalin-evoked pain behavior [67,73,225] to reduce visceral-evoked 
inflammatory states (BoNT/A1) [226], and to attenuate the allodynia otherwise observed in 
mononeuropathies (nerve ligation) and polyneuropathies (as with chemotherapeutics) (BoNT/B1) [84]. 
The specificity of these effects on the role played by the cleavage of SNAREs was provided by two 
observations: i) intrathecal delivery of BoNT/B1 treated with dithiotreitol to cleave the disulfide linkages 
had no activity, and ii) intrathecal BoNT/B1 serotype blocked formalin-evoked flinching in the mouse 
but not in the rat, an observation consistent with the fact that the rat VAMP1 has a mutation at the 
BoNT/B1 targeted cleavage site rendering the rat insensitive to BoNT/B1 activity [227].  
While several lines of evidence indicate that intrathecal BoNT/A1 and /B1 can affect afferent terminal 
function, as reviewed above, they may also be taken up by a variety of neural types including inhibitory 
interneurons (Figure 3, #11). Cell culture studies have shown that several BoNTs can block  
depolarization-evoked release of inhibitory amino acids [92,228–230]. A block of spinal inhibitory 
interneurons would lead to excitation, and such has been reported after accidental intrathecal delivery of 
BoNT/A1 in humans [231]. This is a very important point of consideration when evaluating BoNTs as  
pain pharmaceuticals. 
4.3. Trans-Synaptic Effects 
While the axon transport of active BoNT/A1 and /B1 appears evident, it has long been argued that 
the BoNTs, unlike tetanus toxins, do not undergo trans-synaptic movement. However, current diverse 
findings from several research groups lend support to such a possibility, such that movement to second 
order neurons and glia appears to be a tenable hypothesis (Figure 3, #9#10). Several examples will be noted. 
i) Direct evidence supporting the hypothesis that BoNT/A1 is retrogradely transported in an active 
form and undergoes transcytosis into second order neurons was provided by the detection of BoNT/A1 
cleaved SNAP-25 in tectal synapses after injection of the neurotoxin in the rat eye [191].  
ii) In the trigeminal system, BoNT/A1 injected into the temporomandibular joint inhibited plasma 
extravasation in the dura mater, indicating the likelihood of trans-synaptic movement from mandibular 
afferents to meningeal afferents [74].  
iii) Similarly, in the trigeminal system, BoNT/B1 injected in the supraorbital region blocked 
substance P release (as measured by NK-1 receptor internalization) and c-Fos activation in the ipsilateral 
nucleus caudalis evoked by meningeal capsaicin. This indicates an effect of the subcutaneously delivered 
BoNT/B1 on meningeal afferents [75].  
iv) Cleavage of SNAP-25 in the glial cells of the spinal cord dorsal horn has been observed following 
injection of BoNT/A1 in the paw [232].  
v) Activation of c-Fos can be initiated bilaterally by intrathecal sP through an action on NK1 
receptors. Following unilateral intraplantar BoNT/B1, the ipsilateral (but not contralateral) dorsal horn 
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c-Fos activation is reduced [67]. As the receptors for sP (NK-1R) are postsynaptic to the primary  
afferent [233], ipsilateral block by IPLT BoNT/B1 after bilateral activation is considered to represent an 
effect postsynaptic to the primary afferent terminal.  
vi) Subcutaneous BoNT/A1 reduced the number of c-fos activated neurons following intracisternal 
NMDA injection (Kim et al., 2015) and therefore suggests a trans-synaptic effect. Whether functional 
NMDA receptors are present only post-synaptic is a topic of discussion. 
vii) In rats, a BoNT/A1 and BoNT/A2 serotype injected into a forelimb was observed to produce a 
contralateral weakness, suggesting that the BoNT traveled retrogradely and trans-synaptically to 
contralateral spinal motor neurons [125].  
viii) In humans, BoNT/A1 was found to reduce recurrent inhibition of motor neurons after 
intramuscular BoNT/A1, indicating an effect upon an inhibitory interneuron, consistent with a  
trans-synaptic movement from the motor neuron [202]. These results jointly provide a broad spectrum 
of data in multiple neuraxial systems suggesting that BoNT/A1, B1 and A2 are not only transported to 
the central terminal, but may also undergo trans-synaptic movement from the central afferent terminal 
to second order neurons and glia.  
4.4. BoNT Actions on Glial Cells 
As noted above, DRG satellite cells can release glutamate in a SNARE-dependent fashion and likely 
play a role in regulating local excitability. Similarly, activation of dorsal horn glia and interactions 
between neurons and glia are considered to play a major role in facilitated pain states [234]. Astrocytes 
(and microglia) express a full complement of SNAREs and these regulate their exocytotic activity for 
peptide and amino acids (glutamate) [74,232,235–237]. While some report that astrocytes do not express  
SNAP-25 and instead express BoNT/A1 resistant SNAP-23 [238–240], others demonstrate a decrease 
in neurotransmitter release from astrocytes after BoNT/A1 treatment [241]. In vivo work suggests that 
astrocytes indeed express SNAP-25 [232,242]. Given the role of glial activation in dorsal horn 
sensitization, regulation of their functionality would powerfully regulate dorsal horn facilitated states, 
as after nerve and tissue injury. While currently speculative, this is an important potential aspect of pain 
regulation by BoNTs that requires further exploration (Figure 3, #10). 
5. Diversity of Botulinum Neurotoxins 
Almost all of the above studies have been conducted on the two BoNT subtypes that are currently 
marketed as pharmaceuticals, BoNT/A1 and B1. These studies help in elucidating the mechanisms that 
are involved in inhibition of pain states by BoNT/A1 and /B1. Armed with this constantly increasing 
knowledge base, it is intriguing to consider discovery or design of novel BoNT based pharmaceuticals 
with characteristics that will lead to improved targeting of nociceptive pathways. As reviewed above, 
BoNTs are classified into seven immunologically distinct serotypes (A–G). In addition to the  
well- characterized and defining immunogenic differences [29], the serotypes can also be functionally 
distinguished by several properties. 
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Table 3. Key findings supporting antinociceptive actions of BoNTs after local injection. 
5.1. SNARE Target and Cleavage Sites 
Each BoNT serotype has its own unique SNARE cleavage site. BoNT/A and E both cleave  
SNAP-25 at distinct peptide bonds. BoNT/C also cleaves SNAP-25 at a distinct site and additionally 
cleaves syntaxin [34]. BoNT/B, D, E, and F all cleave synaptobrevin 1 and 2 (VAMP), each at different 
peptide bonds. While the subtypes within one serotype generally all cleave the same SNARE at the same 
No 
Mechanism of 
action 
BoNT 
serotype 
Species/models Interpretations References 
1) 
Local 
Peripheral 
effect 
BoNT/A1/B1
Human/rat/mouse 
Blocks local flare, vasodilation and plasma extravasation 
evoked by local irritants in human and animal studies 
[57–60,66,67, 
74,91,132]  
Human/rat/mouse 
Lack of effect on normal sensory thresholds.  
For e.g. acute thermal and mechanical pain thresholds 
[57,61–63]  
Rat/mouse 
Effective only in facilitated pain states such as activation of 
c-fibers. Does not affect phase I of formalin flinching with 
significant effects on facilitated phase II 
[67–73,117,181] 
2) 
Axonal 
transport 
BoNT/A1/B1
Rat/Cell culture Fast and slow long distance axonal transport in neurons [190–193] 
Cat/rat 
Movement of radiolabeled toxin observed in motor and 
sensory pathways. However, transport of radiolabeled 
isotope per se were not evaluated 
[194–196] 
Rat/mouse 
Cleavage of SNARES in cell body/soma (DRG/TG) i.e., 
away from the site of BoNT injection 
[67,75,197,198] 
Rat/mouse 
Cleavage of SNARES in the central terminals in spinal cord 
following peripheral BoNT 
[67,197] 
3) Central actions 
BoNT/A1/B1 Rat/mouse 
Inhibits substance P release evoked by intrathecal capsaicin 
in spinal cord following peripheral BoNT. Blocking 
neurotransmitter release after retrograde transport. Inhibition 
of nociceptive behavior and neuronal activation of c-fos  
[67,192] 
BoNT/A1 
Rat 
Blocking the axonal transport of peripheral BoNT in 
trigeminal and sciatic nerve using colchicine inhibits 
hyperalgesia 
[71,74,89,197]  
Rat 
Bilateral effect of unilateral BoNT in diabetic neuropathy 
and trigeminal neuropathy 
[74,78,88,89] 
4) 
Trans-synaptic 
actions 
BoNT/A1 Rat 
BoNT is transported from retina to colliculus and 
transcytosed to tectal synapses as observed by SNARES 
cleavage 
[191] 
BoNT/A1/B1
Rat/mouse 
Peripheral BoNT inhibited intrathecal substance P induced 
and intracisternal NMDA induced neuronal activation. 
[67,243] 
Rat/mouse 
Supraorbital BoNT reduced meningeally evoked activation 
of second order neurons and substance P release. BoNT in 
TMJ inhibits dural plasma extravasation 
[74,75] 
BoNT/A2 Rat Peripheral BoNT cleaved SNARES in spinal glial cells [232] 
BoNT/A1 Rat 
Unilateral BoNT produce contralateral muscle weakness and 
bilateral SNARE cleavage 
[125,190] 
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peptide bond, two exceptions are known. BoNT/F5 and a BoNT/FA hybrid toxin [244–246] have a 
unique VAMP1/2 cleavage site [246,247].  
5.2. Membrane Sites Mediating Internalization 
Another very important consideration is that there are membrane sites that mediate the internalization 
of the BoNTs. While for several BoNTs the membrane receptors have been identified, they have not 
been established for all serotypes, and certainly not for all subtypes. All BoNTs seem to associate with 
gangliosides, and specific protein receptors have been identified for several BoNTs (synaptotagmin I 
and II for BoNT/B1 and G, and SV2 for BoNT/A1, D, and E1) [248]. Until recently, the SV2 receptor 
was considered to be the only protein receptor required for BoNT/A1 cell entry in conjunction with 
ganglioside binding [249]. Recently, Fibroblast Growth Factor Receptor 3 (FGFR3) has been suggested 
to also be critical for BoNT/A1 uptake. Overexpression of FGFR3 correlated with increased BoNT/A1 
entry [250], although it is not clear whether the effect is direct or indirect. A direct involvement of 
FGFR3 in BoNT/A1 cell entry might have important implications in the use of this toxin as a pain 
therapeutic. DRGs (e.g., primary afferents) constitutively express FGFR3 and show up-regulation after 
injury [251,252]. FGFR3 is also expressed in astrocytes and microglia, and this expression is upregulated 
by afferent drive [253,254]. Thus, if increased expression of FGFR3 aids BoNT/A1 cell entry, persistent 
afferent activation may lead to an increased up-take of BoNT/A1 into DRGs, astrocytes and microglia. 
This topic requires further exploration.  
5.3. Species Specificity  
Given these distinctions in cleavage sites and membrane binding sites, it is not surprising that there 
are differences in species specificity. BoNT/A, B, E, and F cause human botulism, whereas C and D 
cause botulism in animals, and G is usually not associated with botulism [1]. Rats, but not humans or 
mice, have a single amino acid polymorphism in its VAMP1 sequence that renders it resistant to 
BoNT/B1 [227]. Humans and some rodent species have a polymorphism in VAMP1 that renders it a 
less efficient substrate for BoNT/D [255–257]. In addition, the synaptotagmin II receptor in humans and 
chimpanzees was found to be a weak receptor for BoNT/B1, D-C and G [258,259], which incidentally 
explains the higher dose required for rimabotulinumtoxinB (pharmaceutical BoNT/B1) compared to 
pharmaceutical BoNT/A1.  
5.4. Duration of Action 
Serotypes and even subtypes within one serotype may vary in their duration of action [35,260], 
reflecting differences in intracellular half-life of the LC [261–264]. In humans, durations rank in parallel 
with those noted in vitro and in mice [263,264]: e.g., local intramuscularly delivered BoNT serotypes A, 
B, C, E and F cause local paralysis lasting about 3–6, 3, 2–4, 1–3, and 1–2 months,  
respectively [261,262,264–269]. BoNT/D was poorly effective in causing local muscle paralysis in 
humans [270], and duration of action in mice was significantly shorter than that of BoNT/A1 [271]. 
Given the above distinctions, it is clear that significant differences exist within the serotypes and the 
subtypes for a given serotype that may affect the pharmacological properties of these toxins. Only a few 
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studies so far have analyzed subtype-specific characteristics, and future efforts in that regard will no 
doubt reveal BoNTs with unique properties. Recent studies comparing BoNT/A1–5 have revealed 
significant functional differences between these toxin subtypes, including differential sensitivity of 
various cell-based models, differences in enzymatic activity, differences in symptoms in mice after 
injection of high toxin doses and differences in onset and duration of action [35,272–275]. For example, 
injection of mice with high doses of BoNT/A2 and A3 resulted in an overall increasing paralysis, 
whereas injection with BoNT/A1 and A5 caused typical botulism symptoms, such as ruffled fur, wasped 
waist, difficulty breathing and spasticity just prior to death [272,275]. In addition, the few studies that 
have been undertaken to analyze the cell surface receptors for BoNT subtypes within one serotype 
indicated significant differences [274,276]. These data, in combination with differential sensitivity of 
cell models to these toxins [272], may indicate unique pharmacologic properties of subtypes within one 
serotype. In addition, BoNT/A3 was shown to have a shorter duration of action than BoNT/A1, 2, 4  
and 5 [35,277], whereas BoNT/A2 was shown to enter neurons faster than BoNT/A1 and to be more 
potent in vivo in causing muscle paralysis and central effects [69,125,199,272,274,278–283]. Catalytic 
activity of a few subtypes has also been compared, and these studies have revealed that subtypes within 
one serotype can have distinct substrate binding and cleavage properties [272,273,284], and in the case 
of BoNT/F5 can even have a unique substrate cleavage site [247].  
An initial attempt at redesigning a BoNT with unique pharmacological properties has resulted in the 
creation of BoNT/AE (A1 LC and HC translocation domain, E1 HC receptor binding domain) and 
BoNT/EA (E1 LC and HC translocation domain, A1 HC receptor binding domain) chimeric  
constructs [285]. All constructs resulted in potent muscle paralysis in mice, and the onset and duration of 
action and cell entry properties of these chimeric toxins corresponded to the respective LC-HC-translocation 
domain fragments. Thus, the EA chimera displayed a faster onset of action and shorter duration similar 
to BoNT/E1, whereas the AE chimera had a slower onset and long duration of action similar to 
BoNT/A1. Interestingly, while BoNT/E appears to be unable to bind to and enter trigeminal ganglion 
neurons (TGNs), the EA chimera was found to enter trigeminal ganglion neurons (TGNs) and cleave 
SNAP-25, leading to inhibition of CGRP release, a pain signaling peptide [229]. This study, while not 
directly providing a novel pain-specific therapeutic, demonstrates proof-of-principle that different domains 
of BoNTs can be combined to create unique BoNT based constructs that allow novel neuronal targeting.  
Further research is required to fully elucidate the diversity of this large family of protein toxins, and 
to determine the structural motifs responsible for a particular functional property. Structural studies of 
BoNTs are steadily advancing, and since the first elucidation of the crystal structure of BoNT/A1 in 
1998 [36], high resolution structures of several other serotypes and functional domains have been 
reported 6 analyses have identified amino acid residues required for this binding [286]. These are 
significant advances that, with further detailed studies of other BoNTs and receptor complexes, will 
eventually lead to a better understanding of the structure-function relationships of these toxins and enable 
design of safer and targeted pharmaceuticals.  
6. Future Directions in Botulinum Neurotoxins as Pain Pharmaceuticals 
The complexity of the BoNT structural motif and the ubiquitous role of SNAREs in neuronal function 
emphasize that there are numerous directions for discovery in this field.  
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6.1. Recombinant Technology 
Great advances have been made in analyzing the effects of BoNT/A1 and /B1 on pain conditions. 
However, as discussed above, significantly more research is required to provide a mechanistic 
understanding underlying the analgesic effects of these BoNTs. Interestingly, there seems to be little 
difference in the results observed in pain studies using BoNT/A1 or /B1, even though these two serotypes 
exhibit different characteristics, including different SNARE targets (SNAP-25 for BoNT/A1 and 
VAMP2 for BoNT/B1), different cell surface receptors and different potencies in causing local paralysis 
in humans, and BoNT/A1 has a slightly longer duration of action (see Section 5). For other BoNT  
sero- and subtypes, it is not known whether or how their specific differences impact their effects on 
nociceptive pathways. Considering the large diversity of BoNTs, analyzing various additional BoNTs 
for their utility as therapeutics for pain and other disorders is an exciting area of study. Moreover, 
recombinant techniques in the botulinum neurotoxins field have advanced in recent years to finally 
enable the expression of recombinant BoNTs in heterologous [276,287–290] or native [291,292] 
expression hosts. Such techniques will now allow the design of recombinant BoNT-based constructs that 
are particularly suited as pain therapeutics. Currently such experiments are labor-intensive, expensive 
and restricted in several countries including the United States. However, the potentially huge benefits 
from such studies, such as the development of a pain therapeutic of long duration (weeks to months) 
without impairing side effects, justify the required effort and resources. For example, it has been shown 
that a single amino acid substitution in the LC of BoNT/E resulted in a change in SNARE target cleavage, 
such that the modified LC could efficiently cleave human SNAP-23, which is naturally resistant to 
cleavage by BoNT/E [293]. This is of particular significance for inflammatory pain, as SNAP-23 seems 
to be the major SNAP isoform involved in secretory release in mast cells and in glial cells. Of the BoNTs 
currently identified, several strategies will be cited as examples to further analyze their potential as  
pain therapeutics.  
6.2. Mining through the Diverse Family of BoNTs 
Detailed functional and structural studies of the many not yet characterized BoNT subtypes will likely 
reveal further BoNTs with characteristics that may render them more suitable as pain therapeutics. This 
involves determining the subtype’s unique functional characteristics and the structural features 
responsible for these characteristics, and conducting comparative pain studies to determine which of 
these features would optimize utility of the particular BoNT for pain treatment. Considering the 
relatively few studies characterizing BoNT subtypes so far, finding such characteristics may seem a bit 
like the search for a needle in a haystack. While it is certainly exciting to continue to characterize the 
many BoNT subtypes, more targeted approaches might be possible in the future. By building on the 
recent progress in structure-function studies and on analyses of factors that influence distribution and 
the duration of action of these toxins, modeling studies will likely enable the identification of likely 
candidates or desired structural domains in the future. Based on our current understanding of 
mechanisms involved in pain processing and BoNTs’ effects on such processes, a few strategies for such 
a pursuit are listed below.  
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i) A BoNT or BoNT derivative that specifically or preferentially blocks transmission of pain fibers 
while having a lesser effect on motor neurons and inhibitory interneurons would be expected to be a 
safer alternative to the currently used BoNT/A1 and /B1 for treatment of pain. Due to increased safety, 
larger amounts of the toxin could be applied, which would lead to greater effectiveness and longer 
duration of action. Considering the differences in cell surface receptor binding and species specificity 
among the various BoNTs, future research may identify one or several BoNTs that will preferentially 
enter or affect nociceptive neurons. Several examples of neuronal cell specificity of different BoNTs can 
be found in the literature, including differential sensitivity of various neuronal cell models to  
BoNT/A1-5 [272], unique cell entry properties of BoNT/D in isolated neuronal cultures [271], and 
differential sensitivity of cultured trigeminal ganglion neurons to BoNT/A1, E1, and chimeras  
thereof [229]. In addition, specific toxin characteristics may contribute to distinct pharmacokinetic 
behavior of a particular BoNT subtype, as is evidenced by the observed differences in the pathology and 
local paralysis symptoms of mice injected with BoNT/A1-5 [272,277] as well as by symptomatic 
differences in humans suffering from botulism caused by different serotypes [1]. The pharmacokinetics 
of BoNTs has only been studied for BoNTs that are currently used clinically, and using only a few 
administration routes [294].  
ii) As discussed above, BoNTs have been shown to affect receptor trafficking in target cells. This in 
turn may have profound effects on pain processing. The distinct SNARE cleavage targets and sites of 
the different BoNTs may affect the fusion of endosomes that carry receptors in distinct ways, and further 
research needs to be devoted to this aspect of BoNT function with regard to their effect on pain processes. 
Other factors that may influence receptor trafficking such as intracellular localization also remain  
largely unstudied.  
iii) The involvement of glial cells in pain processing and the development of chronic pain states has 
been well established [74,232,235–237]. Studying the various BoNT subtypes for their potential effects 
on glial cells is of particular interest, as the distinct cell binding and entry mechanisms of the different 
BoNTs raise the possibility that some BoNT types, but not all, may affect glial cells. 
iv) For treatment of chronic pain, a long duration of action is desirable. However, in some instances 
and to prevent the development of (rather than treat) chronic pain, a shorter duration of action (days to 
weeks) may be more appropriate. The duration of action is highly variable for the different BoNTs, and 
the mechanisms underlying the persistence of action of BoNTs in neurons are not well understood. 
Screening of BoNT subtypes for duration of action and pharmacologic properties may detect a BoNT of 
long duration with the desired pharmacologic characteristics, or alternatively enable construction of a 
recombinant BoNT combining the functional domains of different subtypes to achieve the same effect. 
For example, BoNT/A3 has been shown to have a much shorter duration of action in cells and in mice 
than BoNT/A1 [35,277]. Thus, a subtype of the BoNT most widely used for clinical application but with 
a shorter duration of action has now been identified. In addition, this subtype exhibits different cell entry 
kinetics and specificity in various rodent and human cell models [272]. Future studies are required to 
determine its effect on nociceptive processing. 
v) As with current clinical applications of BoNTs, high potency is desirable. Since these toxins are 
proteins, the formation of antibodies and resistance to further treatments are important considerations. 
High potency will reduce the chances of such antibody formation as very small amounts of the toxin can 
be used.  
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vi) Toxin distribution and spread from the injection site likely differs for different BoNTs, as has been 
shown in the case of BoNT/A1 and B1 and BoNT/A1 and A2 [199,278,279]. Toxin spread may 
contribute to antibody formation and increased side effects. It is important to explore how the 
administration route affects toxin spread of the various toxins.  
vii) Finally, ease of production, purification and stability of the toxins are obvious  
important considerations.  
6.3. BoNT/C1 and D1 
An example of specific directions may be exemplified by the considerations of one specific pair of 
toxins. BoNT/C1 and D1 do not produce human botulism but are responsible for large and devastating 
animal botulism outbreaks [295–300]. Both BoNT/C1 and D1 have recently been shown to be in fact 
taken up and be enzymatically active in human neurons [266,271,301]. Many reasons could contribute 
to that, including distribution of the Clostridium strains producing these toxins in the environment, 
uptake of the toxins through the intestinal wall, etc. Interestingly, recent studies of BoNT/D1 have 
indicated that this BoNT serotype cleaves human VAMP1 less efficiently than VAMP1 of most  
animals [255,256]. Local injection in humans resulted in a poor paralytic response [270], most likely 
due to the fact that human motor neurons primarily express VAMP1 [255]. In central neurons, however, 
differential expression of VAMP1 and VAMP2 has been observed [302]. Thus, BoNT/D1 is an 
intriguing toxin to study as a pain therapeutic, as it would be expected to preferentially affect sensory 
neurons expressing VAMP2 over motor neurons, which express mostly VAMP1. Similarly, BoNT/C1 
has been shown to enter neuronal cells by a unique pathway, utilizing dual gangliosides as  
receptors [303]. This unique cell entry pathway is intriguing and analyses of the distribution and 
pharmacology of this toxin will determine whether it may be a useful candidate as a pain therapeutic. 
Even though BoNT/C1 is not usually associated with human botulism, local injection studies in humans 
have shown that it is effective in causing local paralysis [261]. No studies have been conducted assessing 
the effects of BoNT/C1 on pain transmission. While BoNT/C1 is known to cleave two SNARE proteins, 
SNAP-25 and syntaxin [304,305], which has previously been proposed to lead to cytotoxicity [306], 
recombinant technology will now enable selective knocking out of the SNAP-25 or syntaxin cleavage 
in BoNT/C1 holotoxin, which has already been achieved in recombinant BoNT/C1 light chain  
constructs [307]. This will create a novel construct that distributes in vivo as BoNT/C1 but should not 
pose the threat of cytotoxicity. The effect of a toxin only cleaving syntaxin on neuronal transmission 
and, in particular, pain transmission, has never been explored.  
6.4. Alternate Targeting Strategies  
The majority of work reviewed in this overview has considered the effects of 
intramuscular/subcutaneous delivery. Other approaches also lend themselves to delivery of  
pain therapeutics.  
i) Intrathecal delivery of BoNTs represents an important strategy for affecting central processing of 
pain input. As reviewed above, several papers have emphasized that action. However, as noted, such an 
injection may lead to unwanted events because of its broad uptake. An alternate strategy to enhance 
targeting is coupling the toxin to a ligand for a G protein coupled receptor, which will undergo 
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internalization when occupied, carrying the ligand toxin complex with it. One example of such a 
construct is substance P-saporin (sP-saporin), which has been shown to produce a prominent analgesia 
in animals [308–313]. However, saporin results in permanent cell death, which is not a desirable outcome 
for chronic pain treatment. A similar construct utilizing a BoNT LC, with the premise that the LC is not 
readily taken up in the absence of the HC, would be expected to result in the same analgesia due to a 
block in transmission of the treated neurons, but the effect would be long-lasting and reversible. One 
report of such a construct linking substance P to the BoNT/A1 LC did appear to decrease thermal 
hyperalgesia in animals [314], but further work is required to confirm these data and show specificity. 
The use of other targeting ligands raises the intriguing possibilities for specific targeting of neuraxial 
systems. Creation of such targeted secretion inhibitors has been suggested and is pursued by  
industry [315]. Such targeting peptides may be small peptide transmitters that specifically bind to 
receptors on neurons involved in pain processing (such as substance P binding to NK1 receptors), or 
ligands for receptors that are enriched or uniquely displayed on nociceptors, such as the TRPV1  
receptors [316]. One such construct containing the BoNT/A1 catalytic function coupled to lectin has 
been shown to inhibit release of neurotransmitters from DRGs and attenuate sensory transmission from 
nociceptive afferents [317].  
ii) Topical delivery to the skin can result in permeation of the large BoNT structure. Transcutaneous 
movement may be enhanced by several strategies, including the use of synthetic peptides. Such delivery 
has been shown to result in the movement of active forms of BoNT into the skin with effects on afferent 
nerve terminals as evidenced by block of neurogenic inflammation [59]. The potential for such a delivery 
method is strengthened by the observation that cell-permeable forms of a truncated SNAP 25 can 
penetrate the dermis and competitively inhibit SNARE complex formation [318,319]. The effects of the 
unique properties of the different BoNTs on such a delivery strategy are unknown.  
7. Conclusions 
BoNTs comprise a family of protein toxins that are grouped together by their ability to cause botulism 
in humans or animals. Since the first discovery of immunologically distinct serotypes of BoNTs almost 
100 years ago [320], continuing research has revealed the large and diverse nature of this protein family. 
With advances in sequencing methods, structural and biochemical biology and cell culture technologies, 
the past 10–15 years in particular have yielded exciting insights into the variety of BoNTs. Now, over 
40 different subtypes of BoNTs have been described, and the list is likely to grow longer [295,321]. 
Only two BoNTs, BoNT/A1 and BoNT/B1, are currently used clinically, mostly for spasticity related 
disorders and in aesthetics. However, the vast increase in knowledge of this toxin family has now opened 
the door for exploration of these toxins to treat other neurological conditions, such as chronic pain. While 
analyzing the currently marketed BoNTs for that application is of high value, the diverse pool of BoNT 
subtypes provides an additional treasure trove of BoNTs with potentially unique features that may make 
them more suitable as pain therapeutics than BoNT/A1 and /B1. The most critical question in this pursuit 
is, ‘What characteristics would render a particular BoNT or BoNT-based construct more suitable as a 
pain pharmaceutical?’ Only extensive future research on both the mechanism of current clinically used 
BoNTs on pain processing and the effects of the various BoNT subtypes found in nature on pain 
processing will address this question. The rewards of such research efforts are obvious and justify the 
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extensive work required to achieve that goal. Further studies on characterizing the BoNT subtypes may 
also enable the targeted design of recombinant BoNT-based pain therapeutics using specific targeting 
peptides to direct entry of the toxins into pain transmitting neurons. Most interestingly, analyses of the 
effects of BoNTs and targeted derivatives on pain processing will at the same time also advance our 
understanding of the complex mechanisms underlying the encoding of the pain sensation.  
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